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Cancer susceptibility is due to interactions between inherited genetic factors and 
exposure to environmental carcinogens. The genetic component is constituted mainly 
by weakly acting low-penetrance genetic variants that interact among themselves, as 
well as with the environment. These low susceptibility genes can be categorized into 
two main groups: one includes those that control intrinsic tumor cell activities (i.e. 
apoptosis, proliferation or DNA repair), and the other contains those that modulate the 
function of extrinsic tumor cell compartments (i.e. stroma, angiogenesis, or endocrine 
and immune systems). Genome-Wide Association Studies (GWAS) of human 
populations have identified numerous genetic loci linked with cancer risk and behavior, 
but nevertheless the major component of cancer heritability remains to be explained. 
One reason may be that GWAS cannot readily capture gene-gene or gene-
environment interactions. Mouse model approaches offer an alternative or 
complementary strategy, because of our ability to control both the genetic and 
environmental components of risk. Recently developed genetic tools, including high-
throughput technologies such as SNP, CGH and gene expression microarrays, have 
led to more powerful strategies for refining quantitative trait loci (QTL) and identifying 
the critical genes. In particular, the cross-species approaches will help to refine 
locations of QTLs, and reveal their genetic and environmental interactions. The 
identification of human tumor susceptibility genes and discovery of their roles in 
carcinogenesis will ultimately be important for the development of methods for 

















Insight, Innovation, Integration 
Mouse models are an excellent strategy to identify QTLs in a genetically and 
environmentally controlled-manner that could be extrapolated to human populations. 
Additionally, they are very useful to validate and refine candidate loci found in humans 
by GWAS. The integration of new technical innovations has improved QTL research: 
the employment of high resolution SNP, CGH and gene expression arrays speeds up 
the refinement of QTLs. Other technical advances such as whole genome sequencing 
are readily making the recognition of orthologous regions between both species 
straight forward, simplifying the refinement of QTLs found in human and mouse, and 






























Cancer is a highly heterogeneous disease, both in terms of the time of individual 
cancer development, and the biological properties of each tumor. Only a subset of 
human individuals exposed to the same carcinogen, as for example after radiation 
exposure, 1 actually developed a tumor, and even among those who were susceptible, 
tumors did not appear at the same time. Individual tumors also vary enormously in 
terms of tumor evolution and behavior (i.e. local growth, distant dissemination, 
treatment response, and relapse or tumor dormancy). 2-5 Thus, individuals that share 
the same apparent histopathological type of tumor and TNM (Tumor, Node, 
Metastasis) stage, and also receive the same treatment, could have tumors with 
completely different evolutionary histories. 
 One of the most important aspects that remain to be clarified in this field is the 
identification of the genetic and molecular components that determine the diverse 
tumor behaviors among different patients who seemingly have the same 
histopathological disease. It is assumed that most part of the genetic component that 
contributes to this variability is mainly constituted by the sum of actions of weakly 
acting low-penetrance genes, whose allelic forms interact among themselves and with 
the environment to determine the clinical variability among individuals. These genes 
(also called modifier genes), mostly follow a trend of quantitative inheritance6. 
Additionally, a major part of cancer growth is due to non-cell autonomous processes 
that consist in an aberrant tissue growing in an uncontrolled manner within the context 
of the physiology of a complex organism7. Therefore, it is a disease that not only 
depends on the properties of the tumor cells themselves, but also on other 
compartments like the immune and endocrine systems, stroma, vasculature, and 
others, all of which play key roles in the development and evolution of cancer. 
Consequently, differences in tumor behavior are not only determined by intrinsic factors 
to the tumor cells (such as proliferation, apoptosis, etc), but also by extrinsic factors 
outside the tumor compartment per se. Modifier genes could regulate both the 
molecular and cellular functions of these different compartments, and this fact could 
explain the differences in tumor behavior among patients who seemingly suffer the 
same disease. The identification of those modifier genes is one of the major challenges 
of the future in cancer research. In this review we use mainly breast cancer as 
paradigm to illustrate this issue. 
 Genetics analysis strategies are the only tools that allow us to consider the 
global scenario, because the susceptibility loci can contain risk genes controlling either 
intrinsic or extrinsic factors6, 8. Genome Wide Association Studies (GWAS) have 
permitted the identification of different susceptibility regions, genes and pathways, but 
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the reproducibility between studies is difficult, probably due to the high heterogeneity of 
human genetics and its complex interaction with environmental factors6, 8. Crosses 
among inbred mouse strains of defined genetic backgrounds that exhibit strong 
differences in cancer susceptibility, have simplified the identification of Quantitative 
Trait Loci (QTL) and their interactions responsible for variable tumor behavior. Although 
the refinement of the QTLs to the gene level using mouse models was a very difficult 
task, the new high-throughput technologies recently developed in Genetics, Genomics 
and Bioinformatics help to tackle this complicate duty with success. All these new 
technologies are improving our understanding of the genetic component/networks that 
control the variability in tumor risk, development and clinical evolution. The final goal is 
to obtain a better understanding of the molecular factors that determine the variability 
of the disease, which will finally result in the development of more personalized clinical 
applications for the benefit of the patient.  
  
 
Cancer Heritability  
Cancer hereditability is still nowadays very poorly understood. No more than a modest 
portion of cancers present an obvious trend of heredity (the considered “real” 
hereditary cancers). This is actually the situation of breast cancer where just a small 
portion of tumors could be identified by the inheritance of mutated variants of high 
penetrance genes like BRCA1 and BRCA2. However, mutations of these genes only 
account for a small percentage of the human tumor predisposition, resulting in quite 
rare hereditary cancer syndromes. These kinds of uncommon, but severe alleles have 
been additionally implicated in most forms of hereditary cancer syndromes. Hereditary 
susceptibility to breast cancer has become connected with germline mutations in at 
least eighteen genes. 9 A huge number of distinct loss-of-function mutations have been 
discovered within BRCA1 as well as BRCA2 genes; most of these variations are 
usually individually rare, and each one confers quite high susceptibility for breast and 
ovarian malignancies. Uncommon germline mutations of other genes are also 
connected with elevated risk of breast cancer, ranging from two-fold for CHEK2 to ten-
fold for P53. Interestingly, all of these genes function in networks that are crucial to 
DNA repair and preservation of genomic integrity. In most cases, the inherited mutation 
is followed by somatic loss of the corresponding wild type allele, resulting in the 
mistakes in DNA repair that finally lead to cancer development. 10 However, it is 
important to emphasize that only a low percentage of global cancer risk can be 
attributed to hereditary mutations in the high-penetrance care-taker genes, and present 
obvious patterns of Mendelian inheritance.  
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 The environmental component may play a more essential role in sporadic 
tumors than in hereditary cancer, and in the some cases may over-ride the genetics. 11-
13 Nevertheless, there is significant evidence from large scale epidemiological studies 
indicating that the chance of developing sporadic cancer also has a significant 
hereditary component. One of these studies, which was carried out on several 
thousand pairs of twins, demonstrated that when one twin developed cancer, the other 
had a significantly increased risk of generating the same type of disease, but without 
any obvious Mendelian inheritance pattern. In fact, many scientific studies have 
concluded that common cancers are polygenic diseases with a quantitative genetic 
pattern.11-14  
 Even in families carrying specific mutant alleles of high-penetrance risk genes 
with potent effects such as BRCA1 and BRCA2, phenotypes tend to be influenced by 
the hereditary background, becoming much more comparable between affected twins, 
but varying among more distant family members with the same gene alteration; 6,14,15 
this would indicate that low-penetrance genes could also modify the behavior of 
hereditary cancer. A deeper knowledge of the genetic component would be essential to 
estimate the individual genetic susceptibility to develop cancer, to improve early 
detection and diagnosis of the disease, and to understand the fundamental biochemical 
and physiological pathways governed by those low-susceptibility genes as a critical 
step for the development of new cancer treatments. 16  
 
Cancer has a Non-Cell Autonomous Disease Component 
Cancer is in part a non-cell autonomous process; it is an aberrant tissue that grows in 
an uncontrolled manner in the context of the physiology and pathophysiology of a 
complex organism. Tumor growth, as that of any other tissue, depends not only on the 
intrinsic properties of the parenchymal component (tumor cells), but also on other 
organism compartments such as the immune and endocrine systems, stroma, vascular 
system, etcetera (Figure 1). All of them play key roles in the development and evolution 
of cancer. Consequently, tumor behaviour (i.e. susceptibility, development and clinical 
evolution) is not only going to be determined by factors intrinsic to the tumor cell, 
involved in processes such as proliferation, apoptosis, DNA repair etc; but it will also be 
influenced by those extrinsic factors from other compartments. Furthermore, these two 
main compartments are not independent, but rather they continuously crosstalk and 
interact with each other, so that the intrinsic factors are capable of recruiting the 





 The fact is that connections among cancer cells, the stroma and the rest of the 
organism have their roots in the physiological responses that take part in regular tissue 
homeostasis. 17-19 The equilibrium between cell-renewal and cell-reduction is tightly 
governed through connections between parenchyma stem cells and the 
microenvironment to carry out the tissue remodelling or respond to the stress caused 
by tissue injury. Cancer cells virtually do not react in response to normal physiological 
regulators of cell growth, and are constantly sending remodelling signals for the stroma 
to be reorganized in an activated form to permit tumour growth;  to some degree 
tumors behave like a wound that does not heal. 20 Tumor modifier genes could play a 
role in controlling molecular and cellular factors of these two main compartments that 
would explain not only discrete physiological differences among individuals, but also 
differences in the susceptibility, development and the different clinical evolution among 
patients who seemingly suffer the same cancer disease. 
 The relevance of the microenvironment is highlighted by new studies that 
demonstrate how the apparently normal stromal cells can manipulate epithelial cancer 
cell activity in reconstitution experiments, and by recognition of particular somatic 
genetic alterations in the stromal element of the tumor. 21,22 It has been proposed that 
the global microenvironment mostly functions as an epigenetic tumor modifier. 23 In 
fact, the genetic inactivation of Pten in stromal fibroblasts associated with mouse 
mammary glands speeds up the initiation, progression and malignant transformation of 
mammary epithelial tumors. 24 Furthermore, malignant cells can be reverted to a 
quiescent state simply by incorporation into an embryonic microenvironment. 25 This 
suggests the microenvironment is dominating over malignancy. Thus, for tumors to 
advance into a more malignant stage they must change their own microenvironment to 
a promoting one. The change in microenvironment probably originates from oncogenic 
mutations in proliferating tumor cells that send signals to the stroma, but possibly also 
mutations in the stroma itself. 21-24  
 The resulting tumors are complicated structures of malignant cancer cells 
surrounded by vasculature and associated with an active tumor stroma composed of 
several non-malignant cell types, such as fibroblasts and myeloid cells with an 
important role in global tumor behaviour. For example, evidence suggests that tumor 
initiation, progression, as well as metastasis are influenced by particular 
subpopulations of macrophages, 26,27 and also other inflammatory cells, such as B and 
T- lymphocytes and mastocytes, have been shown to play a role in tumor promotion. 28 
In fact, the milieu of the tumor microenvironment is similar to the one found in the 
inflammatory reactions within a restorative healing injury, which stimulates 
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angiogenesis, turnover of the extracellular matrix (ECM), as well as tumor cell motility. 7 
And, as occurs in inflammation, a growing body of data support the perspective that 
extracellular proteinases, like the matrix metalloproteinases (MMPs), mediate 
numerous modifications within the microenvironment in the course of tumor 
development. 29 Additionally, one of the most critical pathways controlling both 
inflammation and tumor microenvironment, is the TGF-beta signalling pathway, 
together with important cell-autonomous effects. GWAS have identified many SNPs 
close to genes that belong to the TGF-beta superfamily, such as CREM1 and SMAD7. 
In addition, constitutively reduced TGFBR1 expression is a powerful modifier of 
colorectal cancer susceptibility. All these data indicate that germline variations of the 
TGF-beta superfamily might account for a very important percentage of colorectal 
cancer susceptibility. 30 
 
 The modulation of stroma function by tumor susceptibility modifier genes is well-
known. The first tumor-modifier gene identified was a modifier of the Apc 
(Adenomatous Polyposis Coli) gene function, located in the QTL named Mom1 
(“Modifier of Min1”, which in turn means “Multiple Intestinal Neoplasia-1”). The gene 
responsible encodes a secretory phosphatase type II phospholipase A (Pla2s). Pla2s 
was proposed to modify polyp number by altering the cellular microenvironment within 
the intestinal crypt. 31 Interestingly, this gene has been widely implicated in the 
inflammatory process, 32 angiogenesis and has pro-atherogenic activity. 33 More 
importantly, later studies demonstrated that the PLA2S gene has a role in human 
cancer pathogenesis of the digestive tract, 34 supporting the importance of mouse tools 
to identify cancer modifier genes in human population. Thus, it is feasible for a number 
of these genetic determinants to be involved in the pathogenesis of different 
physiological and/or pathophysiological events at the same time; this effect is named 
“pleiotropy”. This concept refers to those genes that concurrently have effects on 
different phenotypes. This has been demonstrated not only for the diverse subtypes of 
cancer, such as 8q12 abnormalities that are related with various types of tumors, 35 but 
also for autoimmune diseases 36 or very different pathologic conditions. Many parallels 
exist between different diseases and pathologic situations; for example, hypertension, 
hypercholesterolemia and obesity are included in known metabolic syndrome; or the 
existence of an association between those processes and particular types of cancer; or 
the relationship between certain autoimmune diseases and cancer. 37-39 All of these 
data indicate that complex interactions take place among genes that simultaneously 
control different processes. It is also possible to relate all the disorders that share 
common conditions and the gene interactions that control them. This fact has 
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generated recently the interesting concept of diseasome, 40 which can be represented 
by two networks, first, by the human disease network, in which nodes represent 
disorders, and two disorders are connected to each other if they share at least one 
gene; and second, by a disease gene network where nodes represent disease genes, 
and two genes are connected if they are associated with the same disorder. 40  
 One of the most important challenges in cancer research is to understand the 
underlying basis of heterogeneity of tumor susceptibility, development, and evolution in 
the context of the physiology and pathophysiology of the organism. It would be 
desirable to tackle the cancer problem with tools that permit visualization of  this global 
picture, integrating both intrinsic and extrinsic factors with the behaviour of the tumor 
cell.  Genetic analysis offers a unique tool to embrace the global scenario, because 
each QTL regions could contain both intrinsic and/or extrinsic modifier genes, and can 
help to explain cancer as a complex disease. 
 
Identification of Cancer Susceptibility Genes in Human Populations 
Even though rare alleles with strong effects could be substantial contributors to 
sporadic cancer risk, the searching for tumor susceptibility has been mainly focused on 
the common disease-common variant model that presumes that cancer susceptibility 
originates from the additive effects of combinations of common low-penetrance 
variants. 41 With this model, every susceptibility variant is assumed to contribute a small 
amount of risk, without any variant conferring enough by itself to result in tumor 
development. Cancer origin and evolution have been proposed to be the consequence 
of the merged effects of numerous of such alleles, which may control intrinsic and/or 
extrinsic functions. The search for tumor susceptibility genes has mainly been carried 
out by GWAS, in which allele frequencies at thousands of polymorphic sites (i.e. SNPs) 
are compared in a large number of cases versus a similar number of controls. As 
discussed in later sections, in spite of their limitations, these studies have successfully 
identified some of the common susceptibility variants for different common diseases 
and traits, including cancer 10. 
 
A. Identification of Susceptibility Genes in Breast Cancer 
We will use breast cancer as a model for this discussion,  as major efforts have been 
made to identify  genetic components of both hereditary and sporadic versions of the 
disease. Studies of susceptibility genes in breast cancer initially focused on the 
detection of high-penetrance susceptibility genes through the analysis of linkage in 
family pedigrees comprising several affected members. These familial studies involve 
fewer patients, and need significantly reduced marker density, in comparison with 
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current GWAS, but the two approaches can be complementary. The results of pedigree 
evaluation can offer important and persuasive signs of genetic effects, because they 
are primarily based on genetic transmission of disease-causing alleles between 
affected family members. Inherited variations in the two main susceptibility genes 
already known for breast cancer, BRCA1 and BRCA2, together account for only around 
20% of hereditary breast cancer. 35 A few additional genes have been identified, 42,43 but 
all these known mutations only can elucidate a small portion of familial breast cancers, 
and around less than 5% of the total breast cancer susceptibility. A number of linkage 
studies have described candidate loci that contain breast cancer susceptibility genes. 
However, these loci were not clearly statistically significant presumably due to the fact 
that the number of families affected by each locus was low. In a recent linkage study in 
Spanish breast cancer families, three more regions of interest came out, located on 
3q25, 6q24 and 21q22; 43 it will be very impoprtant to further confirm these results in 
new populations.   
 The majority of the studies to identify susceptibility genes in breast cancer have 
been carried out by GWAS. These studies have identified several common variants 
that have an influence on breast cancer susceptibility, but only four were replicated in 
two or more GWAS (Table 1). 44-51 Meta-analysis of suggestive loci utilizing three 
published GWAS resulted in the detection of an extra locus on 5p12 52 that appeared to 
be linked particularly with estrogen-receptor positive cancers of the breast. It must be 
taken into account that statements for associations with particular categories require 
much more cautious replication studies. For instance, the 2q35 locus was initially 
associated particularly with estrogen-receptor positive breast cancer, but a later study 
reported comparable results irrespective of the estrogen receptor status53 
 Almost all of the individual low-penetrance variations discovered to date have 
weak effects (odds ratios per-allele are less than 1.41) and explain much less of the 
heritability of breast cancer, compared to the known BRCA1 and BRCA2 mutations; 
and maybe a few others such as a common variant within the Fibroblast Growth Factor 
Receptor 2 gene (FGFR2). Nonetheless, a very significant portion of the breast cancer 
susceptibility presently continues to be uncharacterized and may be due to the sum of 
combinations or interactions of low-penetrance genes. These allele variants, together 
with the environmental exposure, may contribute to breast cancer susceptibility. the 
causative environmental exposures continue to be evasive, because many of the 
formerly suggestive environmental and life style risk factors (e.g. nutrition) for breast 
cancer have been recently refuted by large studies in the last decade. 54,55 
 In conclusion, around twenty different presumed breast cancer susceptibility loci 
have already been identified using GWAS studies, but few loci were replicated in 
 11 
different studies. 44 In addition, almost all of these variants identified in breast cancer 
and other studies, have no demonstrated biological or mechanistic relevance to the 
disease, or medical utility for diagnosis or therapy. This could mean that causality 
within this framework can hardly ever be solved by large-scale association or case-
control studies exclusively. 10 A reason for this could be the genetic heterogeneity. A 
number of genes is presumed to play an important role in the susceptibility to breast 
cancer; but those genes could be only important exclusively within a limited amount of 
families, and could be absolutely lost as soon as they are diluted in the general 
population. 16  
 
B. The Challenging of Genome-Wide Association Studies  
Within the last few years, over fifty GWAS have been performed to search for cancer 
susceptibility genes. As discussed by other authors, a few repetitive conclusions can 
be obtained from them: first, only few variants were found in every single GWAS; 
second, each locus has a tiny effect; and third, there is a relative deficit of replication of 
allele variants identified by diverse GWAS. 16 One explanation for this last problem 
could be that, despite having large sample numbers, there is a restricted potential to 
identify modest genetic effects due to the strict levels of significance demanded in 
these studies. Therefore, variants that attain significant p-values, for instance P>10-8, 
are usually real, 56,57 while those associated with significantly more modest P-values 
(e.g. 10-5 or 10-6) might indicate false positives. Furthermore, a large number of those 
variants will not be replicated when screened in other samples. For instance, in GWAS 
the chance that a variant with a P-value of 10-5 shows a genuine association is actually 
lower than one percent. 58,59 
 A different situation that could play a role in clarifying the current incongruence 
of GWAS is the fact that cancer susceptibility is an extremely complicated phenotype 
and, together with the incomplete penetrance of the inherited tumor risk alleles, the 
interaction with environmental risk factors could substantially alter hereditary 
susceptibility. Based on environmental exposures, a person with high genetic 
susceptibility to develop malignancy may well never be affected, while a person at low 
cancer risk, but high exposure,  might suffer the affliction 60 (Figure-2). This question is 
still widely debated for breast cancer, which has been linked to nutritional 61 as well as 
reproductive factors, 62 and alcohol, 63 along with other exposures. Inability to take into 
account this kind of variable in GWAS may well decrease the strength of analysis or 
even reduce our ability to discover genuine causative susceptibility loci. 64 This may 
also clarify the fact that, even though the hereditary element of developing prostate 
cancer was estimated to be around 40% 11, early studies including quite large high risk 
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families have not been confirmed these data. 65 This might be due to genetic 
heterogeneity (i.e. the causal polymorphisms that are the responsible for the phenotype 
vary among families). 
 Additionally, even though quite a few studies have discovered genes with 
important phenotypic effects, 44,47,68-69 as we indicated above, the majority of cancer risk 
is most likely due to a selection of genes with additive effects. It is however also 
possible that many genes regulate cancer susceptibility mainly via non-additive 
interactions. These interactions could be multiplicative or conditional, in such a way 
that the principal effect of one gene would depend on the existence of a specific allele 
within a second locus, and so on, forming a network of gene interactions where the 
next interaction is only possible only if particular allelic form is already present. It might 
be also possible that those numerous weak-interacting loci would simply achieve 
suitable levels of significance within particular series of patient samples, depending on 
the hereditary background or environmental factors (Figure 2). Thus, on top of this 
currently complicated situation of the GWAS scenario would be the spectrum of 
hereditary interactions that depend on the genetic background, a fact that has been 
clearly demonstrated in animal models like the mouse and others. 6,70-72 Moreover, 
genome-wide studies in mouse models of cancer have discovered loci that arise as a 
result of genetic interactions that are not viewed as individual QTL with major effects, 
utilizing common methods of analysis. 70-73 These studies demonstrated, first, the 
power of mouse models to simplify the problem, and second, that more advanced 
statistical methods used to discover interactions among loci in linkage analyses might 
be required to discover the locations of multiple weak susceptibility alleles. 6,74,75 
 In summary, extrapolation of the final results obtained from GWAS to other 
human populations raises the uncomfortable possibility that a specific SNP discovered 
as a tumor modifier in a particular population, however lacks any effect (or even might 
work in the opposite direction) within another ethnic background. For that reason, even 
though hereditary background in individual patients is consequently capable of 
controlling illness development, as it has been evidently demonstrated in animal 
models 76,77 very few of these human low susceptibility genes have been convincingly 
identified. Therefore, even though the present flood of GWAS show the strength of this 
strategy, there are natural restrictions of this whole-genome association analysis that 
circumvent the capture of most pertinent scientific data. Thus, GWAS are afflicted by 
implicit limitations and cannot provide us with an entire understanding of the intricate 
genetic and environmental interactions connected with common disease phenotypes. 
In fact, today no individual method is good enough to permit an extensive knowledge of 
cancer etiology and pathogenesis, in particular within the extremely complicated area 
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of human genetics. But there have been great improvements in QTL research within 
the last ten years, mainly by utilizing mouse cancer models. Mouse QTL analysis as 
well as GWAS will become complementary strategies that will improve the knowledge 
of the actual genetic basis of the human disease. 8  
 
The Mouse as a Complementary Approach 
The use of mouse models can complement human GWAS by allowing a higher level of 
control over hereditary variance and environmental exposure. An intercross or a 
backcross carried out between two inbred mouse strains with divergent tumor 
phenotypes generates offspring where each mouse is genetically and phenotypically 
unique for different quantitative sub-phenotypes controlled by different interacting QTL. 
These strategies reproduce a simplified model of cancer as a polygenic complex 
disease. 8 Furthermore, these approaches are facilitated by the production of a large 
number of inbred and outbreed strains of various Mus species which have different 
evolutionary genealogies, together with recombinant inbred strains, congenics, 69 
consomics, 78 and genetically engineered mice (GEM), all of them constituting a unique 
genetic resource among animal models that can greatly simplify the identification of 
susceptibility genes. Certainly, the enormous number of GEMs available, in particular 
through programs like the Knock-Out Mouse Project (KOMP) whose goal is to mutate 
all protein-encoding genes and make all these mice available to the scientific 
community 79  provide important tools to narrow down QTL candidate genes. Knockouts 
are used in this context to test the candidature of a driver gene at a QTL by what it has 
been named the QTL-knockout interaction test, by which the interaction between the 
null allele and the QTL is tested, and compared with the interaction with the wild type 
allele 80. The use of a GEM strain carrying a knock-out or a knock-in allele located in a 
QTL, can help to validate the participation of that gene in the QTL effect by linkage 
analysis 81. 
 Additionally, there is increasing evidence showing that hereditary risk factors 
have a comparable role in complex disease pathogenesis within human and mouse 
models regardless of interspecies dissimilarities. Rodents develop cancer that appears 
to be amazingly similar in most cases to human tumors, and they accumulate 
mutations in a comparable spectrum involving the same genes and pathways. 82 These 
facts suggest that, at least some of the numerous QTLs containing tumor risk genes 
that have been mapped in the mouse may be highly relevant to the human scenario 
and serve as an effective method of complementing observations within human 
populations. 6 This has been demonstrated for example, for plasma levels of 
cholesterol. 83 Mouse QTLs have already been proven to be equivalent to human 
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disease susceptibility loci in a number of cases including cancer, 84-87 and although 
mouse QTL analysis is not without drawbacks, there have been in the last few years 
important technical advances (see below) (Figure 3). Certainly, the introduction of 
novel techniques and resources can help to unravel the exceptionally complicated 
interwoven factors influencing cancer etiology. These data suggest that mouse studies, 
carried out in parallel with human sample analysis, may accelerate development of a 
deeper understanding of the hereditary risk component of complex diseases 8 (Figure 
4). 
 
Technological Advances for Identification of QTLs in Mouse Models  
Although mouse quantitative trait locus mapping has demonstrated to be an effective 
tool to identify trait risk, this strategy is not without drawbacks. 8 These have prompted 
numerous researchers to examine substitute approaches for candidate gene detection. 
77 Among the drawbacks are low mapping resolution, and secondly, the difficulty of 
identifying specific genes and nucleotides associated with complex genetic traits; 
thirdly,  modelling multiple QTL,  although easier than in GWAS carried out in human 
populations, requires complex statistical strategies. Technological improvements in the 
meantime have partially resolved several of these issues (Figure-3), including: 
 -Analysis of haplotype structure and in silico mapping: Understanding of those 
pieces of the genome that are the same by ancestry (i.e., have the same haplotype 
organization) among mouse strains is a useful approach to refining loci of interest. The 
strategy utilizes genetically more complex mice from natural origin such as partially 
inbred and outbred strains like Mus spretus 86 or heterogeneous stocks generated by 
combinations of various inbred mouse strains. In both cases this strategy may quickly 
minimize the number of candidate genes that have to be tested . 86,88,89 The main idea 
is to identify frequent haplotype sections that segregate inside the genetically 
characterized candidate locus to restrict the quest for presumed genes of interest. 88-91 
 Heterogeneous stock mice like MF1 92 have been developed through the 
arbitrary reproduction of  progeny from normally four to eight inbred strains. 93,94 QTL 
should be found in a region in which sequence divergence matches genetic origin. 
Therefore, whenever QTLs have been mapped in heterogeneous stock populations , 
the markers of strain distribution structure within the initial QTL can be joined with 





This strategy has been utilized to carry out mapping at an exceptionally high resolution 
and to identify candidate genes, 88-90,95 In summary, due to the fact that heterogeneous 
stocks are produced from known ancestral inbred strains, it is possible, by some 
Statistical Genetics and in silico analysis, to obtain the origin of every allele and to map 
QTL at sub-centimorgan resolution.  
 Similarly to the use of heterogeneous stocks of mice artificially generated, is the 
utilization of natural outbred stocks which accumulate recombinants with time, so they 
provide a substantial increase in mapping resolution, possibly sufficient enough to 
identify candidate genes. Specifically, outbred Mus spretus have been utilized with 
successful results to discover Aurora Kinase A (Aurka/Stk6) 96,97 as a skin tumor 
susceptibility gene; 86 and an outbred population of CD1 mice has been utilized to chart 
a predisposing region for lung cancer. 98 These kinds of natural outbred stocks may 
well provide greater resolution than artificial versions; however they miss the benefits 
from parental information within the heterogeneous stocks. In addition, these 
approaches require many animals as well as high density genotyping; in fact, genome-
wide mapping in heterogeneous stocks demands a minimum of 6000 genetic markers 
(i.e. SNPs). It is very important to consider that to reduce false-positive results to 
appropriate levels with such amount of markers it is necessary to utilize strict 
significance thresholds for the p-value. 99,100 
 Recently the Collaborative Cross project was launched to generate the largest 
panel of recombinant inbred (RI) strains with more than one thousand RI lines of mice. 
These strains originated from the crosses among five inbred and three wild-derived 
strains. This strategy will allow high resolution mapping equivalent to the 
heterogeneous stocks, together with the reproducibility of the inbred strains. The main 
aim is to reach a mapping resolution of about a megabase. Additionally, the genetic 
variation will be homogeneously distributed along all the genome without regions where 
there is no variation, so every single gene can potentially be tested for involvement in a 
particular phenotype.101,102 
 -Analysis of tumors using whole genome array comparative genomic 
hybridization (aCGH) and loss of heterozygosity (LOH) analysis by SNP arrays: High 
penetrance germline susceptibility genes, are often linked to somatic loss of the wild 
type allele in tumors (the "two hit" Knudson hypothesis). The same could happen with 
at least some of the low-penetrance susceptibility genes that control intrinsic cellular 
activities. Cancer low-susceptibility genes could drive copy number gains in tumors in 
an allele-specific manner, while cancer resistance alleles may possibly be lost as a 
result of deletion or mitotic recombination leading to loss of heterozigosity (LOH). 
These types of allele-specific somatic losses and gains can be used to identify cancer 
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risk genes; 87,103 this technique facilitated the recognition of Stk6 as a low-penetrance 
tumor susceptibility gene. 86  
 -Genome-wide expression arrays. The observation that most part of SNPs are 
located outside coding regions has led numerous investigators to hypothesize that 
many QTLs are probably attributed to delicate alterations in gene expression instead of 
to missense or nonsense mutations, as is the case for Kras2 in cancer induced by 
urethane. 81 This idea has consequently resulted in the screening for genes in QTL 
regions that exhibit differential expression regarding the strains of interest. 104 This 
particular strategy, initially specified as genetical-genomics, 105 offered a good impartial 
method for quickly screening hundreds of possible candidate genes at the same time to 
reduce the list for additional evaluation to a workable quantity. 90,106 Within this 
technology researchers could include co-regulated networks of expression and QTL 
evaluation: this allows identification of a group of genes that are operating collectively 
to impact a susceptibility phenotype based on the network of genes that are 
significantly correlated with each other, and their expression levels controlled by 
common genetic loci. In some informative circumstances, it would be possible to find 
the susceptibility locus, the candidate gene is affected in cis by that locus, and 
downstream genes which are influenced in trans. Thus, adding automatic finding and 
manual curation it is possible to define networks of genes with a common function and 
that are controlled by a common mechanism. 72, 74, 75  
 -The next generation of sequencing techniques together with the culmination of 
the human 107,108 as well as mouse 109 genome sequencing projects: Thanks to the 
completion of the human genome project it is possible to identify most genes within a 
specified location. Next-generation sequencing will make it possible to investigate 
particular candidate genes without prior genomic screening. The power to discover and 
define candidate loci has continued to grow considerably since the whole genomes of 
many species have been sequenced. 110,111 This has allowed recognition of 
evolutionary conserved sequence domains, and much more recently has allowed direct 
visualizations of SNPs among some of the widely used inbred mouse strains through 
the use of chip-based sequencing, as well as large-scale polymorphism screening. 112 
Interestingly, sequence accessibility throughout species has allowed additional 
speeding of candidate gene recognition for all those traits which have already been 
mapped in several species. Recognition of orthologous chromosomal sections and 
their breakpoints inside genetically identified loci might help to refine QTL localization 
and candidate gene databases by restricting searches to those regions shared 
between the two species. 8,106 
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Future Perspectives for Human Cancer Risk  
As we have discussed, the majority of studies in human families with higher 
cancer susceptibility continue to be centred on the chance that a single or even a small 
number of powerful genes could be the cause of the "missing" hereditary element of 
tumor risk. Even though there may well still be a number of high penetrance genes 
remaining to be discovered, mostly, we will be confronted with the difficulties of the 
existence of numerous low-penetrance modifier genes and their interconnections, as it 
has already been suggested using mouse models of cancer that combinations of these 
low-penetrance modifier genes may be responsible for the variable risk of both 
hereditary and sporadic cancer. 6 In the last years, the efforts to identify this cancer 
genetic component in the human population have been mainly focused on the use of 
GWAS. Although these studies have been proven to be a very useful tool for the 
identification of some common genetic variants, how much this technique has 
contributed to clarification of the "missing heritability" of different complex diseases is a 
matter of controversy. 10,113,114 There have been substantial attempts to recognize low 
penetrance cancer susceptibility genes by GWAS 44,115,116 Even though this research 
has found a few allelic variants which influence cancer risk, the majority of them will 
probably be challenged by this method, because of the tiny impact that any single one 
confers on the total tumor risk. These low penetrance-genes are subject to strong 
interactions among themselves as well as with the natural environment, and the results 
can be quite inconsistent within different populations under the influence of diverse 
environmental elements. Therefore, the actual identification of low penetrance cancer 
risk genes within the human population is a challenging endeavour because of the 
huge heterogeneity within human genetics and the environment. This could explain 
why the majority of the heritable portion of tumor and complex traits has not yet been 
identified by GWAS. For the same reasons, even though some of the genetic loci 
discovered through GWAS initially possess robust statistical significance regarding 
association with specific tumors, the informative potential of these loci to predict 
individual tumor susceptibility is restricted by their small impact on global cancer risk, 
so the clinical importance of this kind of variant will be very limited. Therefore, with our 
current information, we can say that single SNPs will have limited utility in predicting if 
someone will suffer from cancer. But, although the diagnostic benefit of any genetic 
polymorphism alone is limited, we can anticipate that understanding of the combined 
interactions among those allelic variants that collectively possess considerably more 
potent consequences on risk would likely exert a significantly larger effect on the 




Even though mouse models have become an invaluable tool for QTL mapping, a 
refining of QTL locations remains problematic.  This task is beginning to be tackled 
successfully with the help of newly developed technologies such as high throughput 
gene expression arrays together with systems genetics approaches, 74 whole genome 
SNP arrays and aCGH with allele specific analysis, 86 and high-coverage whole 
genome sequencing that will probably become the technique of reference as soon as it 
results cost-effective. In the following years, as a result of the application of these 
technical innovations we ought to start to see the refinement of several loci containing 
mouse cancer risk alleles and also the identification of clusters of them, jointly with their 
interactions, that may help selecting presumed genes and pathways to become 
analyzed in human populations. 6 Moreover, considering the current speed of technical 
advancement, it is quite possible that in the near future, with the advent of new 
technologies such as whole genome sequencing, positional cloning may be 
unnecessary and fine mapping of significant loci may lead straight to their identification.  
 Mouse models not only are a good tool to identify QTL regions that can be 
extrapolated to human populations, but also offer a parallel system for immediate 
testing and verification of the results obtained from human epidemiology and GWAS. 
Also, moving back and forth between mouse and human systems will be a good 
strategy to recognize the causal genetic variant of a presumed candidate gene (Figure-
4). Moreover, it is known that the environmental influences and way of life options have 
an important effect on tumor susceptibility in the humans. Gene-Environment 
interactions could also be investigated using  mouse models, and will allow us to 
recognize how genes work together with particular environmental influences 
recognized by epidemiological studies. Enrolling together systems genetics and 
epidemiology ought to enable us to clarify the connections involving hereditary 
background and environmental factors that are the reason for part of the "obscure" 
cancer heritability. 75  
 The knowledge acquired by means of these genetics studies will have a 
significant effect on medical sciences, and should certainly lead to improved prognosis 
prediction and therapy of human cancer, leading to a more individualized clinical 
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Fig. 1. Cancer is not purely a cell-autonomous disease: There are connections 
between cancer cells and immune and endocrine systems, vasculature and stroma 
surrounding them that modify the tumor behaviour and susceptibility.  
 
Fig. 2. Tumor risk is the consequence of the interaction between constitutional genetics 
and environmental exposures. The combination between the genetic background 
(modifier genes, mainly low susceptibility cancer genes) and the environmental factors 
varies among individuals and might explain the different tumor susceptibility and 
behaviour observed in patients.  
 
Fig. 3. Recent technical advances have improved QTL research: The use of genetically 
more complex mice (outbred and artificial strains) in combination with high resolution 
SNPs arrays and new techniques of statistical genetics greatly improve the definition of 
new QTLs. In tumor cells, the analysis of changes in copy number and expression by 
whole genome comparative hybridization and expression arrays allow the further 
refinement of QTL. 
 
Fig. 4. Mouse models are a good tool to identify QTLs in an environmentally controlled 
way that could be extrapolated to human population. At the same time they are very 
useful to verify and refine candidate loci found in humans by GWAS. Technical 
advances such as whole genome sequencing are readily making the recognition of 
orthologous chromosomal regions between species straight forward simplifying the 





















Table-1: Main regions found by human GWAS for breast cancer susceptibility  
________________________________________________________________ 
Susceptibility Region    Reference  
5q11.2; 8q24; 10q26; 11p15.5; 16q12.1  Easton et al., 2007 44 
2q35; 16q12      Stacey et al., 2007 45 
Three ERBB4 SNPs     Murabito et al., 2007 46 
10q26 (intron 2 of FGFR2)    Hunter et al., 2007 47 
6q22.33      Gold et al., 2008 48 
6q25.1       Zheng et al., 2009 49 
1p11.2; 14q24.1     Thomas et al., 2009 50 
3p24; 17q23      Ahmed, et al., 2009 51 
5p12       Stacey et al., 2008 52 
2q35        Milne et al., 2009 53 
_________________________________________________________________ 
 
